Related Experiment Videos
Prior cytomegalovirus infection does not predict clinical outcome after percutaneous transluminal coronary
A Tiran1, R A Tio, E Oostenveld
1Department of Clinical Immunology, University of Groningen, The Netherlands.andreas.tiran@kfunigraz.ac.at
Insights
This study found that human cytomegalovirus (HCMV) serostatus does not predict restenosis or cardiac events after percutaneous transluminal coronary angioplasty (PTCA). HCMV antibody levels did not correlate with patient outcomes post-PTCA.
Area of Science:
- Cardiology
- Virology
- Immunology
Background:
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA) is a clinical concern.
- Human cytomegalovirus (HCMV) infection has been hypothesized to contribute to restenosis development.
Purpose of the Study:
- To prospectively evaluate the predictive value of HCMV serology for clinical outcomes following PTCA.
- To determine if HCMV infection status influences restenosis rates or cardiac events post-procedure.
Main Methods:
- 112 patients undergoing elective PTCA were enrolled.
- HCMV antibody levels were assessed using ELISA.
- Cardiac events and restenosis requiring revascularization were tracked over a 6-month follow-up period.
Main Results:
- 73% of patients were seropositive for HCMV.
- Among 94 patients with successful PTCA, 33% experienced cardiac events, and 16% had restenosis.
- No significant difference in anginal complaints or revascularization needs was observed between HCMV seropositive and seronegative patients.
- No evidence of acute HCMV reactivation was detected post-PTCA.
Conclusions:
- Patient HCMV serostatus is not associated with clinical outcomes after PTCA.
- Serological markers of HCMV infection do not appear clinically significant for assessing individual patient risk post-PTCA.
- The study does not rule out a potential role for local HCMV reactivation at the angioplasty site.
Background:
A direct association between human cytomegalovirus (HCMV) infection and the development of restenosis after coronary angioplasty has been suggested. The aim of this prospective study was to evaluate the value of HCMV serology in predicting the clinical outcome after percutaneous transluminal coronary angioplasty (PTCA).
Methods And Results:
112 patients undergoing elective PTCA were included in the study. HCMV antibody levels were measured by ELISA. Cardiac events within a follow-up period of 6 months after PTCA were defined as (1) progression or recurrence of anginal complaints and/or a positive exercise test; (2) restenosis that required repeat revascularization. 73% of PTCA patients were seropositive for HCMV. Successful PTCA was achieved in a total of 94 patients, who were followed for 6 months. In 31/94 patients (33%) cardiac events occurred and in 15/94 (16%), this could be related to restenosis. We found no statistically significant difference between seropositive and negative patients with respect to anginal complaints or the need for revascularization. There was no evidence of acute reactivation, since titers of anti-HCMV antibodies did not increase after PTCA.
Conclusion:
This study shows that the clinical outcome after PTCA is not related to the HCMV serostatus of the patient. Therefore, our data do not support the hypothesis that serological markers of HCMV infection are of clinical importance for the assessment of a patient's individual risk after PTCA. This does not preclude a role for local reactivation of HCMV at the site of angioplasty.